NIPPON-SHOKUBAI
20.9.2022 15:31:37 CEST | Business Wire | Press release
NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter “Nippon Shokubai”) (TOKYO:4114) aims to expand our LiFSI* business in China, the biggest market of lithium-ion batteries (hereinafter “LIB”). We hereby announce that, as part of this business expansion, we have reached agreement on investment in Hunan Fluopont New Materials Co., Ltd. (hereinafter “Hunan Fluopont”), a subsidiary of Shenzhen CAPCHEM Technology Co. Ltd. (hereinafter “Capchem”), who is currently making efforts to establish production facilities to enter LiFSI business.
*Lithium bis (fluorosulfonyl) imide (Product name: IONEL™), a lithium salt as the advanced electrolyte which was commercialized first in the world by Nippon Shokubai.
1. Background of the alliance
With a rising awareness of environmental issues in recent years, there is a high demand for electric vehicle (EV), which is an industry-leading product of energy-saving and low-pollution next-generation vehicles, and this has led to the rapid expansion of the LIB market for EV. Because using LiFSI as an electrolyte in LIB for EV significantly improves the battery’s cyclic and rate performance as well as storing stability over a wide temperature range from low to high temperatures, LiFSI has been adapted not only as an additive, but also as a main ingredient of the electrolyte. As this has led to a surge in LiFSI demand particularly in Asia and Europe, early business expansion to China, the world’s biggest LIB market for vehicles has been a key for us to make a big leap in our IONEL™ business.
2. Purpose of the alliance
Under these circumstances, in order to acquire high-profile customers and early establish a cost-competitive manufacturing and sales structure in China with the largest LIB demand, we have decided to form an alliance with Capchem, a major electrolyte solution manufacturer, and Toyota Tsusho Corporation (Headquarters: Nagoya, Japan, President: Ichiro Kashitani, hereinafter “Toyota Tsusho”), who is Toyota Group’s general trading company. The investment will be made by Toyota Tsusho (Shanghai) Co., Ltd. (hereinafter “Toyotsu Shanghai”). This will allow us to combine our state-of-the-art LiFSI production technologies, quality control capability, and intellectual properties with Hunan Fluopont’s cost-competitiveness, location, material procurement capability, production system, and existing technologies, and Capchem’s LiFSI purchasing capability supported by their top-level supply capacity of electrolyte solutions, as well as Toyota Tsusho’s world-wide sales network encompassing China. Through this alliance, we will aim to accelerate our IONEL™ business in the electrolyte market.
LiFSI is known as a difficult substance to purify to a high degree, which is only achieved by advanced know-how for its production and quality management. Using our unique production technology that we have nurtured over the years, in 2013, we succeeded in the development of an industrial production process of highly-pure LiFSI with few solvents and by-products, exhibiting stable electrochemical properties, for the first time in the world. Our product has been adopted and certified as the electrolyte by many LIB manufacturers inside and outside Japan with a wide variety of applications including vehicle, consumer-use, and stationary batteries.
(For details of LiFSI, please refer to our website: https://www.shokubai.co.jp/en/lp/ionel/)
Capchem is the world’s second largest manufacturer of electrolyte solution for LIB with five production sites in China, and has a track record of providing its products to major LIB manufacturers. Their business includes not only manufacturing of electrolyte solution, but also in-house material production of solvent, electrolyte, additive, which enables them to offer electrolyte solution with price competitiveness and high quality.
Toyota Tsusho is looking to expand their LiFSI sales beyond China to electrolyte solution manufactures in Japan, Asia, and Europe to meet the surging demand in the electrolyte solution and electrolyte markets.
Hunan Fluopont started its production in the second half of FY2022 with the first unit (production capacity 1,200t/y). It is planned to be expanded in stages to satisfy the rapidly increasing market demand, aiming to have annual production capacity of 12,000 ton/y in 2025.
3. Investment overview
Nippon Shokubai and Toyotsu Shanghai will invest in the following company. |
||
(1) |
Company name |
|
|
Hunan Fluopont New Materials Co., Ltd. |
|
(2) |
Location |
|
|
Shigu District, Hengyang, Hunan, China |
|
(3) |
Amount invested (third-party allocation of shares) |
|
|
Nippon Shokubai: 201,769,912 RMB (4.04 billion JPY) |
|
|
Toyotsu Shanghai: 29,203,539 renminbi (580 million JPY) |
|
|
[Assumed exchange rate: 20 JPY/RMB] |
|
(4) |
Shareholders |
|
|
Capchem: 51.19% |
|
|
Nippon Shokubai: 38.0% |
|
|
Toyotsu Shanghai: 5.5% |
|
|
Changsha ShinLian Huayuan Alternative Energy Partnership Enterprise (shareholding association by executive employees of Hunan Fluopont): 5.31% |
|
(5) |
Representative |
|
|
Shu Ping Ai |
|
(6) |
Businesses |
|
|
Manufacturing and sales of electrolyte LiFSI for LIB |
|
(7) |
Production capacity |
|
|
Current: 1,200t/year in the second half of FY2022 |
|
|
Plan: 12,000t/year in FY2025 |
|
Related information
Profile of Shenzhen CAPCHEM Technology Co. Ltd. |
|
Company Name |
Shenzhen CAPCHEM Technology Co. Ltd. |
Location |
Capchem Plaza, Changye Road, Pingshan District, Shenzhen, Guangdong Province, China. |
Establishment |
1996 |
Capital |
410 million RMB (8.2 billion JPY) (as of end of 2021) |
Total assets |
223.3 billion JPY (as of end of 2021) |
Sales |
139 billion JPY (FY2021) |
Operating profit |
30.8 billion JPY (FY2021) |
Business overview |
Lithium battery chemicals, organic fluorine chemicals, capacitor chemicals and semiconductor chemicals. For lithium-ion battery electrolytes in mass production at five production sites in China and several other production sites under construction in China and Poland. |
Website |
|
Profile of Toyota Tsusho Corporation |
|
Company Name |
Toyota Tsusho Corporation |
Location |
9-8, Meieki 4-chome, Nakamura-ku, Nagoya 450-8575 Japan |
Establishment |
1948 |
Capital |
64.9 billion yen (as of end of March 2022) |
Total assets |
6,143.1 billion yen (as of end of March 2022) |
Sales |
8,028 billion yen (FY 2021) |
Operating profit |
294.1 billion yen (FY 2021) |
Business overview |
As a general trading company of Toyota Group, the company has expanded its business with a focus on exports of vehicles and automobile production support. The company has seven business fields (Metals, Global Parts & Logistics, Automotive, Machinery, Energy & Project , Chemicals & Electronics, , Food & Consumer Services, and Africa). and focuses on three core businesses, Mobility business that contributes to future convenient society, Resources & Environment business that contributes to sustainable society and Life & Community business that contributes to comfortable & healthy society. Around 65,000 Group employees are engaged in business in about 130 countries. |
Website |
|
Profile of Toyotsu Shanghai |
|
Company Name |
TOYOTA TSUSHO (SHANGHAI) CO.,LTD. |
Location |
1717 Nanjing West Road, Jinganqu, Shanghai, China |
Establishment |
1995 |
Capital |
33.18 million RMB (660 million JPY) (as of end of March 2022) |
Business overview |
The company mainly operates trading businesses with a wide variety of business units including Metal, Global and Logistics, Chemical Products and Electronics, Mechanical and Energy Plant Project, Food and Household Items, and East Asia Next Mobility Promotion Project. |
About NIPPON SHOKUBAI: Since 1941, Nippon Shokubai has grown up its business with unique catalyst technology. Nippon Shokubai has supplied, for example, ethylene oxide and acrylic acid. Among all, our production capacity of superabsorbent polymers is the largest in the world (according to Nippon Shokubai research). We are currently focused on the Solutions Business, and IONEL (LiFSI) mentioned on this announcement plays a key role in accelerating the business. Nippon Shokubai is a global chemical company operating under its corporate mission “TechnoAmenity - Providing prosperity and comfort to people and society, with our unique technology.”
https://www.shokubai.co.jp/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908006154/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
Cegid Closes Acquisition of Shine to Create Europe's First Complete AI-Driven Platform for SMBs and Accountants8.6.2026 09:28:00 CEST | Press release
Accelerates Cegid’s trajectory to become the leading European financial solutions hub integrating e-invoicing, accounting, digital finance, payment services and accounts, and HR solutionsTransaction supported by new €1.1 billion debt financing facility secured from leading direct credit funds, underscoring Cegid’s strong business performance and unique leadership positioning in rapidly evolving software sector Cegid, a European leader in cloud management solutions for professionals in the finance (treasury, tax, ERP), human resources (payroll, talent management), accountancy, retail and entrepreneurship sectors, today announced the completion of its acquisition of Shine. The transaction creates the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe. Shine – a fast-growing European fintech unicorn providing electronic invoicing, accounting, business accounts, and payroll software to small and medium-sized businesses across Eu
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
